HC Wainwright reaffirmed their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. StockNews.com cut shares of Ocular Therapeutix […]
JMP Securities restated their market outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $24.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a buy […]
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with.
Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates: 3/10/2024 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 3/2/2024 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/26/2024 – Ocular […]